Stocks to Watch: Nvidia Partners with SK Hynix, Marvell and Flex Join S&P 500
Several companies are experiencing notable stock movements due to partnerships and index changes, which could influence investor sentiment and market dynamics.
Roche
Prezzo: 51.65Società e modello di business
Roche is a global healthcare company specializing in pharmaceuticals and diagnostics. Its core products include prescription medications, particularly in oncology, immunology, and neuroscience, as well as diagnostic tools for various diseases. Major business segments are Pharmaceuticals and Diagnostics, with primary revenue sources stemming from drug sales and diagnostic testing services. The company is known for its strong research and development capabilities, contributing to its innovative product pipeline.
Profilo di investimento
Roche's investment profile is characterized by a balanced approach, appealing to investors seeking both growth and dividends. The company offers a stable dividend yield, making it attractive for income-focused investors, while its strong revenue growth indicates potential for capital appreciation. This combination positions Roche as suitable for those looking for a reliable investment with moderate risk.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 2.73 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 90.4% ↑
- Volatilità 20g
- 1.8% stabile
- Rendimento dividendo
- 3.1% moderato ultima data ex-dividendo: 2026-03-13
Dati FMP / FinFeed aggiornati:
2026-06-11
Racc.: Compra
Potenziale: 67
Rischio: 35
Aggiornato: 2026-06-13 02:58
Come funziona la raccomandazione
Perché l'AI la pensa così:
Strong fundamentals and solid dividend yield support growth.
Traccia in portafoglio
Grafico prezzo
Raccomandazione AI
Previsione analista
Evento calendario
Segnale positivo
Segnale negativo
Neutrale / aggiornamento
Mantieni / informativo
B My buy
S My sell
Cambiamenti di raccomandazione AI
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-05 02:47 | Vendi | Compra | Strong revenue growth, but mixed momentum signals. |
| 2026-06-03 02:51 | Mantieni | Vendi | Weak momentum and high risk limit upside potential. |
| 2026-06-01 02:49 | Compra | Mantieni | Solid fundamentals, but mixed momentum signals present uncertainty. |
Previsioni analisti
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2025-12-10 11:17 | HSBC | Target alzato | 50 → 57 | 48.66 |
| 2025-10-02 09:07 | HSBC | Rating migliorato | — → 50 | 44.83 |